BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
A total of 300 new bisphosphonates were screened for their effect on bone resorption in the rat. Among these, 1-hydroxy-3-(methylpentylamino)propylidenebisphosphonate (BM 21.0955) was selected for detailed investigation. It inhibited arotinoid-stimulated bone resorption as assessed by calcemia in thyroparathyroid-ectomized rats at a SC dose as low as 0.001 mg P (0.016 μmol) per kg body weight per day. The compound was thus about 2, 10, 50, and 500 times more potent than risedronate, alendronate, pamidronate, and clodronate, respectively. Intravenous administration was as effective as subcutaneous, and oral administration was 100 times less effective. The effect after one administration decreased with time but was still measurable after 2 weeks. Nonstimulated bone resorption assayed by the urinary excretion of radiolabeled tetracycline from lifelong prelabeled animals was also inhibited. This effect started 3 days after a single dose and was still maximal after 7 days. Histomorphometric analysis of the tibial metaphysis in growing intact rats also showed an inhibition of bone resorption along with an increase in bone mass. The number of osteoclasts increased in animals treated with 0.01 and 0.1 mg P per kg (0.16 and 1.6 μmol/kg) body weight SC but decreased in animals given 1 mg P per kg (16.1 μmol/kg), showing that the inhibition of bone resorption was not due to an inhibition of osteoclast recruitment. No inhibition of mineralization occurred. This new bisphosphonate appears to have great potential for use in human bone disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bisphosphonates do not appear to suppress osteoclastogenesis (129, 140, 141)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [141]
Citations
Cites
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P., Woodson, G. C., Yanover, M. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 949
Storm, T., Thamsborg, G., Steiniche, T., Genant, H. K., & Sorensen, O. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221803 · Cited by 935
Fleisch, H., Graham, R., Russell, G., & Francis, M. D. (1969) · Science · doi:10.1126/science.165.3899.1262 · Cited by 758
Self-citationHandbook of Experimental Pharmacology
(1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-68-1-269_2 · Cited by 727
Francis, M. D., Graham, R., Russell, G., & Fleisch, H. (1969) · Science · doi:10.1126/science.165.3899.1264 · Cited by 608
Self-citationThe Role of Phosphonates in Living Systems
Hilderbrand (2018) · CRC Press eBooks · doi:10.1201/9781351076470 · Cited by 544
Brown, W. A. B. (1985) · FEBS Letters · doi:10.1016/0014-5793(85)81367-3 · Cited by 495
Schenk, R., Merz, W. A., Mühlbauer, R., Russell, R. G. G., & Fleisch, H. (1973) · Calcified Tissue Research · doi:10.1007/bf02547219 · Cited by 482
Self-citationTwo modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.
Boonekamp, P. M., van der Wee-Pals, L. J. A., LENNEP, M. V., Cw, T., & Bijvoet, O. L. (1986) · PubMed · Cited by 345
Russell, R. G. G., Mühlbauer, R. C., Bisaz, S., Williams, D. A., & Fleisch, H. (1970) · Calcified Tissue Research · doi:10.1007/bf02196199 · Cited by 341
Self-citation
Research works printed but not linked: 8
- Kanis, 1987, Clodronate – a new perspective in the treatment of neoplastic bone disease, Bone (Suppl.), 8, S1
- Burckhardt, 1989, Disodium Pamidronate (APD) in the Treatment of Malignancy-Related Disorders
- Charhon, 1986, Histomorphometric analysis of bone biopsies of baboons treated with “SR 41319BH,” a new diphosphonate (abstract), Calcif Tissue Int, 38, 124
- Bevan, 1988, Bisphosphonate action in the oophorectomized rat: The effects of 2-(3-pyridinyl)-1-hydroxyethylidene-bis(phosphonate) on skeletal metabolism; comparison with etidronate (abstract), J Bone Miner Res (Suppl.), 3, 498
- Valentin-Opran, 1990, Risedronate: Preliminary results of a pharmacologic study in pagetic patients. Twelfth Annual Meeting of the American Society for Bone and Mineral Research, Atlanta, Georgia, August 28–31, 1990 (abstract 182), J Bone Miner Res, 5
- Mühlbauer, 1990, A method for continual monitoring of bone resorption in the rat: Evidence for a diurnal rhythm, Am J Physiol, 259, R679
- Schenk, 1984, Methods of Calcified Tissue Preparation, 1
- Mühlbauer, 1989, 1-Hydroxy-3-(methylpentyl-amino)propylidene-bisphosphonate (BM 21.0955), a potent new inhibitor of bone resorption. Tenth International Conference on Calcium Regulating Hormones and Eleventh Annual Meeting of the American Society for Bone and Mineral Res, Montréal, Québec, Canada, September 9–14, 1989, J Bone Miner Res, 4
Cited by
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
“Ibandronate is a highly potent nitrogen-containing bisphosphonate((17)) that has the potential to be administered intermittently with extended between-dose intervals.”
BackgroundBisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,124
Bisphosphonates: Mechanisms of Action
Fleisch, H. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,019
Self-citationCellular and molecular mechanisms of action of bisphosphonates
Rogers, M. J., Gordon, S., Benford, H. L., Coxon, F. P., Luckman, S. P., Monkkonen, J., & Frith, J. C. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.0.co;2-l · Cited by 977
Bisphosphonates: mechanisms of action.
Rodan, G. A., & Fleisch, H. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118722 · Cited by 921
Self-citationDunford, J. E., Thompson, K., Coxon, F. P., Luckman, S. P., Hahn, F. M., Poulter, C. D., Ebetino, F. H., & Rogers, M. J. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38786-5 · Cited by 900
“or tertiary nitrogen function in the R(2) side chain, for example, PAM, ALN, IBA and INC, which have an alkyl R(2) side chain (Schenk et al., 1986; Mühlbauer et al., 1991; Rogers et al., 2000), or RIS, ZOL and MIN, which have a heterocyclic R(2) side chain (Sietsema et al.”
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 648
Fleisch, H. (1991) · Drugs · doi:10.2165/00003495-199142060-00003 · Cited by 581
Self-citationBisphosphonates: Mode of Action and Pharmacology
Russell, R. G. G. (2007) · Pediatrics · doi:10.1542/peds.2006-2023h · Cited by 503
Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
Green, J. R., Müller, K., & Jaeggi, K. A. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090521 · Cited by 415
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.
Sahni, M., Guenther, H. L., Fleisch, H., Collin, P., & Martin, T. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116422 · Cited by 412
Self-citationBisphosphonates: From Bench to Bedside
RUSSELL, R. G. G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.041 · Cited by 410
The relationship between the chemistry and biological activity of the bisphosphonates
Ebetino, F. H., Hogan, A.-M. L., Sun, S., Tsoumpra, M. K., Duan, X., Triffitt, J. T., Kwaasi, A. A., Dunford, J. E., Barnett, B. L., Oppermann, U., et al. (2011) · Bone · doi:10.1016/j.bone.2011.03.774 · Cited by 391
Osteoblast proliferation and maturation by bisphosphonates
Im, G.-I., Qureshi, S. A., Kenney, J., Rubash, H. E., & Shanbhag, A. S. (2004) · Biomaterials · doi:10.1016/j.biomaterials.2003.11.024 · Cited by 393
Miller, P. D., Mcclung, M. R., Macovei, L., Stakkestad, J. A., Luckey, M., Bonvoisin, B., Reginster, J.-Y., Recker, R. R., Hughes, C., Lewiecki, E. M., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050313 · Cited by 333
“Ibandronate is a potent, nitrogen-containing bisphosphonate.((28)) Potency, combined with favorable tolerability((10)) and bone-binding characteristics,((29)) allow ibandronate to”
BackgroundReginster, J.-Y., Adami, S., Lakatos, P., Greenwald, M., Stepan, J. J., Silverman, S. L., Christiansen, C., Rowell, L., Mairon, N., Bonvoisin, B., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044958 · Cited by 326
Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.
van der Pluijm, G., Vloedgraven, H., van Beek, E., van der Wee-Pals, L., Löwik, C., & Papapoulos, S. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118841 · Cited by 305
Price, P. A., Faus, S. A., & Williamson, M. K. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.5.817 · Cited by 301
Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption
Vitte, C. (1996) · Endocrinology · doi:10.1210/en.137.6.2324 · Cited by 299
Self-citationRogers, M. J., Watts, D. J., & Russell, R. G. G. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1652::aid-cncr15>3.0.co;2-z · Cited by 285
The pharmacology of bisphosphonates and new insights into their mechanisms of action
Russell, R. G. G., Rogers, M. J., Frith, J. C., Luckman, S. P., Coxon, F. P., Benford, H. L., Croucher, P. I., Shipman, C., & Fleisch, H. A. (1999) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650140212 · Cited by 279
Self-citationDelmas, P. D., Adami, S., Strugala, C., Stakkestad, J. A., Reginster, J., Felsenberg, D., Christiansen, C., Civitelli, R., Drezner, M. K., Recker, R. R., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21918 · Cited by 258
“Because ibandronate is a highly potent inhibitor of bone resorption (10), it can also be administered as a rapid IV injection over 15–30 seconds, with extended dose-free intervals.”
BackgroundYoneda, T., Sasaki, A., Dunstan, C., Williams, P. J., Bauss, F., De Clerck, Y. A., & Mundy, G. R. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119435 · Cited by 247
“We then examined the effects of a combination of TIMP-2 overexpression and ibandronate, another potent bisphosphonate (14), compared with those of each single treatment.”
ResultSelf-citationHiraga, T., Williams, P. J., Mundy, G. R., & Yoneda, T. (2001) · PubMed · Cited by 256
Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro
Benford, H. L., McGowan, N. W. A., Helfrich, M. H., Nuttall, M. E., & Rogers, M. J. (2001) · Bone · doi:10.1016/s8756-3282(01)00412-4 · Cited by 235
Fulfaro, F., Casuccio, A., Ticozzi, C., & Ripamonti, C. (1998) · Pain · doi:10.1016/s0304-3959(98)00135-3 · Cited by 196
“Ibandronate is a third generation bisphosphonate, 80 times more potent than Pamidronate (Muhlbauer et al., 1991), which was tested successfully in several studies on patients with tumour-induced hypercalcemia (Wuster et al., 1993; Pecherstorfer et al., 1996a).”
BackgroundThree Monthly Intravenous Injections of Ibandronate in the Treatment of Postmenopausal Osteoporosis
Thiébaud, D., Burckhardt, P., Kriegbaum, H., Huss, H., Mulder, H., Juttmann, J. R., & Schöter, K. H. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00249-0 · Cited by 186
Sauty, A., Pecherstorfer, M., Zimmer-Roth, I., Fioroni, P., Juillerat, L., Markert, M., Ludwig, H., Leuenberger, P., Burckhardt, P., & Thiébaudi, D. (1996) · Bone · doi:10.1016/8756-3282(95)00448-3 · Cited by 176
Recker, R., Stakkestad, J. A., Chesnut, C. H., Christiansen, C., Skag, A., Hoiseth, A., Ettinger, M., Mahoney, P., Schimmer, R. C., & Delmas, P. D. (2004) · Bone · doi:10.1016/j.bone.2004.01.008 · Cited by 172
“The potential to administer ibandronate as a convenient intravenous injection (as opposed to an extended intravenous infusion) was suggested by the results of a preclinical study, which indicated that ibandronate was 2–500 times more potent than older bisphosphonates in suppressing bone resorption in rats [13].”
ResultDiel, I. J., Body, J.-J., Lichinitser, M. R., Kreuser, E. D., Dornoff, W., Gorbunova, V. A., Budde, M., & Bergström, B. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.03.025 · Cited by 166
Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures
Nishikawa, M., Akatsu, T., Katayama, Y., Yasutomo, Y., Kado, S., Kugai, N., Yamamoto, M., & Nagata, N. (1996) · Bone · doi:10.1016/8756-3282(95)00426-2 · Cited by 161
Adachi, H., Igarashi, K., Mitani, H., & Shinoda, H. (1994) · Journal of Dental Research · doi:10.1177/00220345940730081301 · Cited by 163
Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
Virtanen, S. S., Väänänen, H. K., Härkönen, P. L., & Lakkakorpi, P. T. (2002) · PubMed · Cited by 162
(2008) · PubMed · Cited by 160
Menssen, H. D., Sakalová, A., Fontana, A., Herrmann, Z., Boewer, C., Facon, T., Lichinitser, M. R., Singer, C. R. J., Euller-Ziegler, L., Wetterwald, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.032 · Cited by 159
Ravn, P., Clemmesen, B., Riis, B. J., & Christiansen, C. (1996) · Bone · doi:10.1016/s8756-3282(96)00229-3 · Cited by 151
Ibandronate: A Clinical Pharmacological and Pharmacokinetic Update
Barrett, J., Worth, E., Bauss, F., & Epstein, S. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004267594 · Cited by 150
Self-citationIbandronate in osteoporosis: preclinical data and rationale for intermittent dosing
Bauss, F., & Russell, R. G. G. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1612-7 · Cited by 148
“When compared in rats, the highest dose tested in this respect (1.0 mgP/kg/ day s.c., corresponding to 5.14 mg free acid equivalents / kg) [22] is >300 times the therapeutic dose in metastatic bone disease [68, 69], >500 times the therapeutic dose in malignant hypercalcemia [ 22 ], and >5,000 times the therapeutic dos…”
BackgroundInfluentialSelf-citationDallas, S. L., Garrett, I. R., Oyajobi, B. O., Dallas, M. R., Boyce, B. F., Bauss, F., Radl, J., & Mundy, G. R. (1999) · Blood · doi:10.1182/blood.v93.5.1697 · Cited by 137
Self-citationIgar, K., Adachi, H., Mitani, H., & Shinoda, H. (1996) · Journal of Dental Research · doi:10.1177/00220345960750090501 · Cited by 137
Kim, H. K. W., RANDALL, T. S., Bian, H., Jenkins, J., Garces, A. H., & Bauss, F. (2005) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.d.02192 · Cited by 131
Self-citationDose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia
Ralston, S. H., Thiébaud, D., Herrmann, Z., Steinhauer, E., Thurlimann, B. J. K., Walls, J., Lichinitser, M., Rizzoll, R., Hagberg, H., Huss, H., et al. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.48 · Cited by 129
Pecherstorfer, M., Herrmann, Z., Body, J., Manegold, C., Degardin, M., Clemens, M., Thurlimann, B. J. K., Tubiana-Hulin, M., Steinhauer, E. U., Eijkeren, M. V., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.268 · Cited by 124
Fructooligosaccharide Consumption Enhances Femoral Bone Volume and Mineral Concentrations in Rats
Takahara, S., Morohashi, T., Sano, T., Ohta, A., Yamada, S., & Sasa, R. (2000) · Journal of Nutrition · doi:10.1093/jn/130.7.1792 · Cited by 123
Pataki, A., Müller, K., Green, J. R., Ma, Y. F., Li, Q. N., & Jee, W. S. S. (1997) · The Anatomical Record · Cited by 113
Smith, S. Y., Recker, R. R., Hannan, M. T., Müller, R., & Bauss, F. (2003) · Bone · doi:10.1016/s8756-3282(02)00923-7 · Cited by 105
Self-citationIbandronate in the treatment of prostate cancer associated painful osseous metastases
Heidenreich, A., Elert, A., & Hofmann, R. W. (2002) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500574 · Cited by 106
“6 Since ibandronate is approximately 50 times more potent than pamidronate and 500 times more potent than clodronate in inhibiting osteoclastic bone resorption in animal models”
BackgroundRiis, B. J., Ise, J., Von Stein, T., Bagger, Y., & Christiansen, C. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.10.1871 · Cited by 100
The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats
Kurth, A. H. A., Eberhardt, C., Müller, S., Steinacker, M., Schwarz, M., & Bauss, F. (2005) · Bone · doi:10.1016/j.bone.2004.12.017 · Cited by 99
Self-citationChesnut, C. H., Ettinger, M. P., Miller, P. D., Baylink, D. J., Emkey, R., Harris, S. T., Wasnich, R. D., Watts, N. B., Schimmer, R. C., & Recker, R. R. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x30752 · Cited by 98
Ringe, J. D., Dorst, A., & Faber, H. (2005) · Osteoporosis International · doi:10.1007/s00198-005-2001-6 · Cited by 96
“bisphosphonate [19] with proven efficacy in the management of metastatic bone disease [20–23], postmenopausal osteoporosis [24–35], and corticosteroid-induced osteoporosis [36].”
BackgroundUpdate of current therapeutic options for the treatment of postmenopausal osteoporosis
Epstein, S. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.02.007 · Cited by 106
Monier-Faugere, M.-C., Geng, Z., Paschalis, E. P., Qi, Q., Arnala, I., Bauss, F., Boskey, A. L., & Malluche, H. H. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.10.1768 · Cited by 94
“It prevents retinoid-induced hypercalcemia in thyroparathyroidectomized rats at lesser doses than risedronate (2×), alendronate (10×), pamidronate (50×), and clodronate (500×).((37)) Also, we have previously demonstrated that ibandronate at the low dose of 1 mg/kg was able to prevent completely the bone loss occurring…”
BackgroundResultSelf-citationColeman, R. E., Purohit, O. P., Black, C., Vinholes, J., Schlosser, K., Huss, H., Quinn, K. J., & Kanis, J. A. (1999) · Annals of Oncology · doi:10.1023/a:1008386501738 · Cited by 95
“Bisphosphonates are known to show dose-dependent inhibition of retinoid-induced hypercalcaemia in the thyroparathyroidectomized rat, and in this model ibandronate was found to be about 2, 10, 50 and 500 times more potent than risedronate, alendronate, pamidronate and clodronate respectively [12].”
BackgroundAlendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats
Bushinsky, D. A., Neumann, K. J., Asplin, J. R., & Krieger, N. S. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00247.x · Cited by 94
The Effect of the Bisphosphonate Ibandronate on Breast Cancer Metastasis to Visceral Organs
Michigami, T., Hiraga, T., Williams, P. J., Niewolna, M., Nishimura, R., Mundy, G. R., & Yoneda, T. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1019905111666 · Cited by 93
“The BP ibandronate [20] (provided by Boehringer Mannheim GmbH, Mannheim, Germany, currently Roche) was diluted with PBS and the pH was adjusted to 7.”
MethodMüller, R., Hannan, M., Smith, S. Y., & Bauss, F. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040809 · Cited by 90
Self-citationKim, T.-W., Yoshida, Y., Yokoya, K., & Sasaki, T. (1999) · American Journal of Orthodontics and Dentofacial Orthopedics · doi:10.1016/s0889-5406(99)70290-8 · Cited by 97
Use of bisphosphonates in cancer patients
Body, J., Coleman, R. E., & Piccart, M. J. (1996) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(96)90020-1 · Cited by 92
New bisphosphonates in osteoporosis
Fleisch, H. A. (1993) · Osteoporosis International · doi:10.1007/bf01623222 · Cited by 91
“In animals, however, the number of osteoclasts is often increased, even though bone resorption is blocked [16].”
BackgroundSelf-citationPrice, P. A., Caputo, J. M., & Williamson, M. K. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.7.1171 · Cited by 93
“Because these alendronate doses do not inhibit normal bone mineralization,((10)) the failure of alendronate to generate the serum mineral complex is compatible with the hypothesis that the complex is generated by the acute inhibition of bone mineralization.”
BackgroundInhibitory effect of a bisphosphonate (risedronate) on experimental periodontities in rats
Shoji, K., Horiuchi, H., & Shinoda, H. (1995) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.1995.tb02134.x · Cited by 80
Rationale for the use of alendronate in osteoporosis
Kanis, J. А., Gertz, B. J., Singer, F. R., & Ortolani, S. (1995) · Osteoporosis International · doi:10.1007/bf01623652 · Cited by 89
Bauss, F., Wagner, M., & Hothorn, L. H. (2002) · PubMed · Cited by 77
Self-citationFelsenberg, D., Miller, P. D., Armbrecht, G., Wilson, K., Schimmer, R. C., & Papapoulos, S. E. (2005) · Bone · doi:10.1016/j.bone.2005.05.004 · Cited by 81
Treatment of Osteoporosis with Bisphosphonates
Watts, N. B. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70194-0 · Cited by 81
Stuible, M., Moraitis, A., Fortin, A., Saragosa, S., Kalbakji, A., Filion, M., & Tremblay, G. B. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.494542 · Cited by 70
“Evaluation of in vivo efficacy was adapted from the methods described by Schenk and co-workers (18) using very young mice that have rapidly growing bones.”
MethodBikle, D. D., Morey-Holton, E. R., Doty, S. B., Currier, P. A., Tanner, S. J., & Halloran, B. P. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650091115 · Cited by 72
Nakamura, M., Ando, T., Abe, M., Kumagai, K., & Endo, Y. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15972.x · Cited by 71
Optimizing orthodontic treatment in patients taking bisphosphonates for osteoporosis
Zahrowski, J. J. (2009) · American Journal of Orthodontics and Dentofacial Orthopedics · doi:10.1016/j.ajodo.2008.08.017 · Cited by 85
Lühe, A., Künkele, K., Haiker, M., Schad, K., Zihlmann, C., Bauss, F., Suter‐Dick, L., & Pfister, T. (2008) · Toxicology in Vitro · doi:10.1016/j.tiv.2008.01.006 · Cited by 68
Self-citationInhibitory effects of bisphosphonate (YM175) on bone resorption induced by a metastatic bone tumor
Hiraga, T., Tanaka, S., Yamamoto, M., Nakajima, T., & Ozawa, H. (1996) · Bone · doi:10.1016/8756-3282(95)00428-9 · Cited by 66
Neudert, M., Fischer, C., Krempien, B., Bauss, F., & Seibel, M. J. (2003) · International Journal of Cancer · doi:10.1002/ijc.11397 · Cited by 65
Self-citationRogers, M. J., Watts, D. J., Russell, R. G. G., Ji, X., Xiong, X., Blackburn, G. M., Bayless, A. V., & Ebetino, F. H. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090710 · Cited by 73
Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection
Pecherstorfer, M., Ludwig, H., Schlosser, K., Buck, S., Huss, H., & Body, J. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110506 · Cited by 64
New bisphosphonates in the treatment of bone metastases
Averbuch, S. D. (1993) · Cancer · doi:10.1002/1097-0142(19931201)72:11+<3443::aid-cncr2820721611>3.0.co;2-3 · Cited by 64
Monier‐Faugere, M., Friedler, R. M., Bauss, F., & Malluche, H. H. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650081109 · Cited by 61
Self-citationPATHOGENESIS AND MANAGEMENT OF BONE LESIONS IN MULTIPLE MYELOMA
Bataille, R., Manolagas, S. C., & Berenson, J. R. (1997) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70435-4 · Cited by 59
Lalla, S., Hothorn, L. A., Haag, N., Bader, R., & Bauss, F. (1998) · Osteoporosis International · doi:10.1007/bf02672503 · Cited by 59
Self-citationBone as an Effect Compartment: Models for Uptake and Release of Drugs
Stepensky, D., Kleinberg, L., & Hoffman, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342100-00001 · Cited by 68
Åstrand, J., & Aspenberg, P. (2002) · Acta Orthopaedica Scandinavica · doi:10.1080/000164702317281369 · Cited by 52
“Clodronate is about 50 times less effective than alendronate (Muehlbauer et al. 1991).”
BackgroundMühlbauer, R. C., & Fleisch, H. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117875 · Cited by 52
Self-citationSchimmer, R. C., & Bauss, F. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90005-1 · Cited by 56
Self-citationUse of Bisphosphonates to Improve the Durability of Total Joint Replacements
Shanbhag, A. S. (2006) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/00124635-200604000-00003 · Cited by 52
Mitsuta, T., Horiuchi, H., & Shinoda, H. (2002) · Journal of Periodontology · doi:10.1902/jop.2002.73.5.479 · Cited by 49
Effects of bisphosphonate on the remodeling of rat sagittal suture after rapid expansion.
Lee, K., Sugiyama, H., Imoto, S., & Tanne, K. (2001) · PubMed · doi:10.1043/0003-3219(2001)071<0265:eobotr>2.0.co;2 · Cited by 49
Alendronate prevents bone loss and improves tendon‐to‐bone repair strength in a canine model
Thomopoulos, S., Matsuzaki, H., Zaegel, M. A., Gelberman, R. H., & Silva, M. J. (2007) · Journal of Orthopaedic Research® · doi:10.1002/jor.20293 · Cited by 48
Update on Osteoporosis Management in Long-term Care: Focus on Bisphosphonates
Kamel, H. K. (2007) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2007.06.005 · Cited by 47
Sohara, Y., Shimada, H., Scadeng, M., Pollack, H. A., Yamada, S., Ye, W., Reynolds, C. P., & DeClerck, Y. A. (2003) · PubMed · Cited by 48
Bauss, F., Schenk, R., Hört, S., Müller‐Beckmann, B., & Sponer, G. (2004) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2003.11.003 · Cited by 46
Self-citationEndo, Y., Shibazaki, M., Yamaguchi, K., Nakamura, M., & Kosugi, H. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702367 · Cited by 45
Tartronates: A New Generation of Drugs Affecting Bone Metabolism
Caselli, G., Mantovanini, M., Gandolfi, C. A., Allegretti, M., Fiorentino, S., Pellegrini, L., Melillo, G., Bertini, R., Sabbatini, W., Anacardio, R., et al. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.6.972 · Cited by 45
Bergner, R., Dill, K., Boerner, D., & Uppenkamp, M. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.7.1281 · Cited by 45
“A similar prevention of bone resorption is achieved with ibandronate at 10-fold lower doses compared with aminobutane bisphosphonate, and 2-fold lower doses compared with risedronate, which so far has been considered the most potent known bisphosphonate [3–5].”
BackgroundComparative Clinical Pharmacology and Therapeutic Use of Bisphosphonates in Metabolic Bone Diseases
Rosen, C. J., & Kessenich, C. R. (1996) · Drugs · doi:10.2165/00003495-199651040-00003 · Cited by 45
Anticalcification and antiresorption effects of bisacylphosphonates
Gelder, J. M. V., Breuer, E., Ornoy, A., Schlossman, A., Patlas, N., & Golomb, G. (1995) · Bone · doi:10.1016/8756-3282(95)00081-n · Cited by 44
Long-term effects of clodronate on growing rat bone
Lepola, V., Hannuniemi, R., Kippo, K., Laurén, L., Jalovaara, P., & Väänänen, H. K. (1996) · Bone · doi:10.1016/8756-3282(95)00439-4 · Cited by 49
Acute Renal Effects of Intravenous Bisphosphonates in the Rat
Pfister, T., Atzpodien, E., Bohrmann, B., & Bauss, F. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_160.x · Cited by 43
Self-citationBisphosphonates in osteoporosis: An introduction
Fleisch, H. A. (1993) · Osteoporosis International · doi:10.1007/bf01623000 · Cited by 42
“compounds [5], with the value for alendronate being about”
Self-citationIbandronate uptake in the jaw is similar to long bones and vertebrae in the rat
Bauss, F., Pfister, T., & Papapoulos, S. E. (2008) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-007-0837-x · Cited by 41
“Subcutaneous administration of ibandronate is as effective as IV in the prevention of stimulated bone loss in rats, thus refl ecting complete bioavailability by this route of administration [ 8 ].”
BackgroundSelf-citation
Metadata
- Authors
- Mühlbauer, R. C., Bauss, F., Schenk, R., Janner, M., Bosies, E., Strein, K., & Fleisch, H.
- Affiliations
- University of Bern (CH)
- Boehringer Mannheim, Mannheim, Germany
- Corresponding author
- Mühlbauer, R.C.
- ORCID
- Janner, M.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1991-09-01
- Volume
- 6
- Issue
- 9
- Pages
- 1003-1011
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2012291531
- Cited by
- 239
- References
- 30
- Citations by year
- 2023: 1 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 1 · 2015: 2 · 2014: 4 · 2013: 3 · 2012: 3
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- bisphosphonates, bone resorption inhibition, osteoclasts, risedronate, alendronate, pamidronate, clodronate, bone mass, bone histomorphometry
- MeSH terms
- Risedronic Acid, Pamidronate, Ibandronic Acid, Animals, Benzoates, Bone Resorption, Calcium, Clodronic Acid, Diphosphonates, Injections, Intravenous, Osteoclasts, Retinoids, Etidronic Acid, Spectrophotometry, Atomic, Tetracycline, Thyroxine, Alendronate, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.